Mehmet Salih Iyikesici
- Specialization: Hematologist/oncologist
- 29 years of experience
- Speaks:English, Turkish
- Workplace: Turkey, Istanbul, Central Hospital
- Medical oncologist specializing in MSCT; author of peer-reviewed work on MSCT in rectal cancer (2020) and on outcomes in NSCLC and breast cancer (2004).
Assoc. Prof. Dr. Mehmet Salih İyikesici is a medical oncologist. He provides personalized care for breast, lung, and gastrointestinal cancers. He combines metabolically supported therapies with chemotherapy. His interests include the ketogenic diet in cancer care, hyperthermia, and hyperbaric oxygen therapy.
He has conducted and contributed to national and international scientific studies. Selected national peer-reviewed publications include Metabolic Supported Chemotherapy in Rectal Cancer (2020), NSCLC Patient Outcomes – Marmara University (2004), and Early-Stage Breast Cancer Outcomes (2004).
Doctor's services
How are we doing?
Qualifications
Assoc. Prof. Dr. Mehmet Salih İyikesici is a Medical Oncology specialist. He provides personalized treatment, particularly for breast, lung, and gastrointestinal cancers, using metabolically supported therapies, chemotherapy, and innovative approaches. He has conducted and contributed to national and international scientific studies
Areas of Interest • Medical Oncology • Metabolic Supported Chemotherapy (MSCT) • Ketogenic diet in cancer treatment • Hyperthermia therapy • Hyperbaric oxygen therapy • Breast cancer • Lung cancer • Colorectal cancer • Pancreatic cancer
Publications in National Peer-Reviewed Journals • Metabolic Supported Chemotherapy in Rectal Cancer (2020) • NSCLC Patient Outcomes – Marmara University (2004) • Early-Stage Breast Cancer Outcomes (2004)
You may also be interested
Payment & Rewards
You don’t pay for our services
You make your payment directly at the clinic or to their official bank account.
Some clinics may require a deposit as a part of their policy.
Spread out your payments with installment options.
Earn rewards for referring friends to Bookimed.